¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѽÅÀåÇÐȸ Á¦13ȸ Nephrology Board Review Course 2019 : 2019-02-09

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇѽÅÀåÇÐȸ Á¦13ȸ Nephrology Board Review Course 2019 : 2019-02-09
±³À°ÀÏÀÚ : 2019-02-09
±³À°Àå¼Ò : ¼­¿ï, ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ(¿ë»ê±¸ ÀÓÁ¤·Î 26 ¼ÒÀç)  
±³À°ÁÖÁ¦ : Á¦13ȸ Nephrology Board Review Course 2019
ÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ
´ã´çÀÚ : »ç¹«±¹ ¿¬¶ôó
¿¬¶ôó : 02-3486-8736  
À̸ÞÀÏ : ksn@ksn.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 30ºÐ  
¼¼ºÎ¼ö°­·á : 80,000¿ø      
ºñ°í       

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 09:10~09:40 Metabolic acidosis of CKD: pathogenesis, consequences, and treatment  Áֱǿí(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 09:40~10:10 Hypokalemia: clinical perspectives on endocrine connections  ±è¼ö¿Ï(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 10:10~10:40 Dysnatremia in patients with neurologic disorders  ±è¼¼Áß(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 10:50~11:15 Pathology and mechanisms of glomerular diseases  ÀÓ¹üÁø(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 11:15~11:40 Nephrotic syndrome (focusing on MCD and FSGS)  ±èÈ¿»ó(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 11:40~12:05 Membranous nephropathy (idiopathic and secondary)  ¿ÀÁöÀº(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 13:05~13:30 Membranoproliferative glomerulonephritis and C3 glomerulopathy  ¿À¼¼¿ø(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 13:30~13:55 Treatment of IgA nephropathy based on pathologic classification  ÀÌÇÏÁ¤(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 13:55~14:20 Paraprotein-related kidney disease  ÀÌÁ¤Àº(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 14:30~14:55 Effect of low salt and protein diet in CKD progression  À̼º¿ì(À»ÁöÀÇ´ë) 
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 14:55~15:20 Optimal therapeutic strategies for CKD-MBD  Á¤Áö¿ë(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 15:20~15:45 Diabetic kidney disease (current and future strategies)  ÇѽÂÇõ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 15:45~16:10 Hyperuricemia in CKD  ¹ÝÅÂÇö(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 16:10~16:35 Medical management of obesity in CKD  ±Ç¼ø±æ(ÃæºÏÀÇ´ë) 
±³À°½Ã°£ 02-09 ÄÁº¥¼ÇȦ 16:35~17:00 Update on renovascular disease  ±èÅÂÈñ(ÀÎÁ¦ÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѽÅÀåÇÐȸ Á¦13ȸ Nephrology Board Review Course 2019 : 2019-02-09""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇѽÅÀåÇÐȸ Á¦13ȸ Nephrology Board Review Course 2019 : 2019-02-10
´ÙÀ½±Û °¡Å縯´ëÇб³¼­¿ï¼º¸ðº´¿ø °¡Å縯´ëÇб³ »êºÎÀΰúÇб³½Ç ¿¬¼ö°­Á : 2019-01-27
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
360 ¼­¿ï ´ëÇÑÀçÈ°ÀÇÇаúÀÇ»çȸ 2018 Ãß°èÇмú´ëȸ : 2018-09-09 1 1,042 2018-08-08
359 ¼­¿ï 2018³âµµ ³úÆÄÁ¤µµ°ü¸®À§¿øȸ Á¤±â±³À° : 2018-09-09 0 663 2018-08-08
358 °æ³² Á¦1ȸ µ¿ºÎ°æ³²Çмú´ëȸ : 2018-09-08 0 846 2018-08-08
357 ¼­¿ï °æÈñ´ëÇб³º´¿ø ¹é¹ÝÁõ°ú »ö¼ÒÁúȯ : 2018-09-08 0 829 2018-08-08
356 ¼­¿ï ´ëÇÑ°áÇÙ¹×È£Èí±âÇÐȸ Asthma School 2018 : 2018-09-08 0 365 2018-08-08
355 ¼­¿ï 2018³â ´ëÇѳëÀÎÀçÈ°ÀÇÇÐȸ Ãß°èÇмú´ëȸ : 2018-09-08 0 396 2018-08-08
354 ºÎ»ê 2018 ´ëÇѾȰúÀÇ»çȸ 5Â÷ ½ÉÆ÷Áö¿ò : 2018-09-08 0 716 2018-08-08
353 ºÎ»ê ´ëÇÑôÃß¿Ü°úÇÐȸ ºÎ¿ï°æ ´ë±¸ÇÕµ¿ ôÃßÁöȸ ¼¼¹Ì³ª : 2018-09-08 0 573 2018-08-08
352 ±¤ÁÖ ´ëÇÑôÃß¿Ü°úÇÐȸ 2018 ±¤ÁÖ±¹Á¦Ã´Ãß½ÉÆ÷Áö¿ò : 2018-09-08 0 304 2018-08-08
351 ÃæºÏ Á¦14Â÷ ´ëÀüÃæû¼Ò¾Æ½Å°æÁöȸ ½ÉÆ÷Áö¾ö : 2018-09-08 0 720 2018-08-08
350 ¼­¿ï 2018³â ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À° : 2018-09-07 0 718 2018-08-08
349 ¼­¿ï ¼­¿ï¾Æ»êº´¿ø À̺ñÀÎÈÄ°ú ±Ý¿äÁý´ãȸ : 2018-09-07 0 445 2018-08-08
348 ºÎ»ê ÁÁÀº°­¾Èº´¿ø Áø·á½Ç¿¡¼­ ÈçÈ÷ º¸´Â Áõ»óÀÇ Á¢±Ù°ú Ä¡·á : 2018-09-06 0 602 2018-08-08
347 ºÎ»ê ´ëÇѺñ´¢±â°úÇÐȸ ¼Ò¾Æºñ´¢ÀÇÇÐ ¹× ³²¼ºÀÇÇÐ : 2018-09-06 0 840 2018-08-08
346 ±¤ÁÖ ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ Á¦281Â÷ Àü³²Áöȸ Áý´ãȸ : 2018-09-06 0 365 2018-08-08
1371 | 1372 | 1373 | 1374 | 1375 | 1376 | 1377 | 1378 | 1379 | 1380
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷